Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM

This study has been terminated.
(The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.)
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01160237
First received: July 8, 2010
Last updated: February 21, 2012
Last verified: February 2012

July 8, 2010
February 21, 2012
August 2010
February 2011   (final data collection date for primary outcome measure)
Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies for Each Vaccine Strain, in Subjects Aged 18-60 and Above 60 Years [ Time Frame: 21 days after vaccination ] [ Designated as safety issue: No ]
Humoral immune response in terms of Haemagglutination Inihibition (HI) antibodies for each vaccine strain, in subjects aged 18-60 and above 60 years [ Time Frame: 21 days after vaccination ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01160237 on ClinicalTrials.gov Archive Site
  • Solicited Local and General Symptoms [ Time Frame: During 7 days (Day 0 - Day 6) after vaccination ] [ Designated as safety issue: No ]
  • Number of Subjects Reporting Unsolicited Adverse Events [ Time Frame: During 31 days (Day 0 - Day 30) after vaccination ] [ Designated as safety issue: No ]
  • Number of Subjects Reporting Serious Adverse Events [ Time Frame: During the whole study period (Day 0 - Day 182) ] [ Designated as safety issue: No ]
  • Potential Immune Mediated Diseases [ Time Frame: During the whole study period (Day 0 - Day 182) ] [ Designated as safety issue: No ]
  • Humoral Immune Response in Terms of HI Antibodies Against Each Vaccine Strain, at Different Timepoints in Subjects Aged 18-60 and Above 60 Years [ Time Frame: At Days 0, 7 and 182 ] [ Designated as safety issue: No ]
  • Solicited local and general symptoms [ Time Frame: During 7 days (Day 0 - Day 6) after vaccination ] [ Designated as safety issue: No ]
  • Unsolicited adverse events [ Time Frame: During 31 days (Day 0 - Day 30) after vaccination ] [ Designated as safety issue: No ]
  • Serious adverse events [ Time Frame: During the whole study period (Day 0 - Day 182) ] [ Designated as safety issue: No ]
  • potential Immune Mediated Diseases [ Time Frame: During the whole study period (Day 0 - Day 182) ] [ Designated as safety issue: No ]
  • Humoral immune response in terms of HI antibodies against each vaccine strain, at different timepoints in subjects aged 18-60 and above 60 years [ Time Frame: At Days 0, 7 and 182 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM
Immunogenicity and Safety of FluarixTM/ Influsplit SSW® 2010/2011 or Pandemrix TM

The aim of this study is to evaluate the immune response and the safety of one injection of FluarixTM/ Influsplit SSW® 2010/2011 or Pandemrix TM in subjects who had received a single Pandemrix TM dose at least 6 months preceding study inclusion. Subjects never vaccinated with any H1N1 pandemic vaccine will be enrolled as control.

This Protocol Posting has been updated following Amendment of the Protocol, July 2010. The impacted section is entry criteria.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Influenza Infection
  • Biological: Pandemrix™
    One dose intramuscular injection
  • Biological: Fluarix™/ Influsplit SSW® 2010/2011
    One dose intramuscular injection
  • Experimental: Pandemrix Group
    Subjects previously vaccinated with Pandemrix received 1 dose of Pandemrix.
    Intervention: Biological: Pandemrix™
  • Experimental: Fluarix Group
    Subjects previously vaccinated with Pandemrix received one dose of Fluarix.
    Intervention: Biological: Fluarix™/ Influsplit SSW® 2010/2011
  • Active Comparator: Control Group
    Subjects not previously vaccinated with Pandemrix received one dose of Fluarix.
    Intervention: Biological: Fluarix™/ Influsplit SSW® 2010/2011
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
7
February 2011
February 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who the investigator believes can and will comply with the requirements of the protocol. Specific attention should be given to the compliance potential of subjects with suspected or known drug and alcohol abuse.
  • Subjects who have received one dose of Pandemrix at least 6 month before enrolment, to be enrolled in the Groups A or B OR subjects who have not been previously vaccinated with a vaccine against the pandemic H1N1 strain at all, to be enrolled in group C.
  • A male or female 18 years and above at the time of enrolment.
  • Written informed consent obtained from the subject.
  • Healthy subjects or free of acute aggravation of the health status as established by physical examination before entering into the study.
  • Female subjects of non-childbearing potential may be enrolled in the study.
  • Female subjects of childbearing potential may be enrolled in the study.

Exclusion Criteria:

  • Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period.
  • Administration of any influenza vaccine within 6 month prior to vaccination in this study.
  • Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
  • Presence of an axillary temperature ≥ 37.5ºC, or acute symptoms greater than "mild" severity on the scheduled date of first vaccination.
  • Diagnosed with cancer, or treatment for cancer, within the past 3 years.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.
  • Chronic administration of immunosuppressants or other immune modifying drugs within 6 months of study enrolment or planned administration during the study period..
  • Any administration of a long-acting immune-modifying drug (within 3 months before study start, or a planned administration during the study period.
  • Receipt of any immunoglobulins and/or any blood products within 3 months of study enrolment or planned administration of any of these products during the study period.
  • Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin outside of 24 hours prior to vaccination are eligible. Persons receiving prophylactic antiplatelet medications, e.g., low-dose aspirin, and without a clinically-apparent bleeding tendency, are eligible.
  • An acute evolving neurological disorder or history of Guillain-Barré syndrome.
  • Clinically or virologically confirmed influenza infection within 6 months preceding the study start.
  • Administration of any vaccines within 30 days before vaccination.
  • Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.
  • Pregnant or lactating female
  • Female planning to become pregnant or planning to discontinue contraceptive precautions from study inclusion up to 2 months after completion of the vaccination series.
  • Any conditions which, in the opinion of the investigator, prevents the subjects from participating in the study.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01160237
114454
Not Provided
Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP